Al-Mahrouqi Haitham Hilal, Ganesh Anuradha, Al-Rawas Abdulhakim, Khetan Vikas, Al-Zuhaibi Sana
Department of Ophthalmology, Ministry of Health, Al-Nahdha Hospital, Muscat, Sultanate of Oman.
Department of Pediatric Ophthalmology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.
Oman J Ophthalmol. 2021 Oct 20;14(3):187-189. doi: 10.4103/ojo.ojo_107_21. eCollection 2021 Sep-Dec.
A 3-year-old child was incidentally found to have chronic myelogenous leukemia (CML) during an admission for a routine ophthalmic examination under anesthesia. The child had received systemic chemotherapy and focal treatment for Groups C and D retinoblastoma in the right and left eye, respectively, when she was 7 months old. CML was treated with dasatinib, and the child attained a major molecular response. The child is now 3 years after treatment of CML, and the retinoblastoma remains inactive. CML following treatment of retinoblastoma is a rare occurrence. Long term and close monitoring of retinoblastoma patients who received systemic chemotherapy using serial blood tests is essential.
一名3岁儿童在全麻下进行常规眼科检查入院期间偶然发现患有慢性粒细胞白血病（CML）。该儿童7个月大时，右眼和左眼分别接受了针对C组和D组视网膜母细胞瘤的全身化疗和局部治疗。CML采用达沙替尼治疗，患儿获得了主要分子反应。该患儿目前处于CML治疗后3年，视网膜母细胞瘤仍未进展。视网膜母细胞瘤治疗后发生CML很罕见。对接受全身化疗的视网膜母细胞瘤患者进行长期密切监测并进行系列血液检查至关重要。
